U.S. Markets closed

Journal of Drugs in Dermatology Publishes Study Showcasing Clinical Improvements with Burt’s Bees’ Sensitive Skin Regimen as Adjunct to Rosacea Prescription Therapy

(Photo: Business Wire) Multimedia Gallery URL

DURHAM, N.C.--(BUSINESS WIRE)--

Data Demonstrating Regimen’s Outperformance of a Dermatologist-Recommended Control to be presented at American Academy of Dermatology Annual Meeting

Burt’s Bees, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of Burt’s Bees skin care products as an adjunct to rosacea prescription therapy. Abstracts outlining the study data will be shared at the American Academy of Dermatology Annual Meeting on March 1-5, 2019, in Washington, D.C.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190213005152/en/

The nature-based regimen clinically and statistically improved investigator-rated redness (erythema) by 28%; spider veins (telangiectasia) by 26% and pimple-like skin lesions (papules/pustules) by 34% (p<0.001) whereas a control synthetic regimen improved rosacea symptoms by 8 to 12%. Differences between treatments were statistically significant. Overall skin appearance measured by the investigator was clinically and statistically improved from baseline by 32% and 12% with the nature-based regimen and control regimens, respectively. No clinically significant tolerability issues were reported for either regimen at week four.

“Rosacea can be a difficult condition to manage representing an important subset of sensitive skin. Carefully designed cleansers and moisturizers are important to maximize treatment results,” said Zoe Draelos, MD, President, Dermatology Consulting Services, PLLC, High Point, NC, the study’s principal investigator. “The data suggest that products made with nature-based ingredients can be effective when used in conjunction with prescription therapies.”

This ten-week, single-site controlled, product-blinded study was conducted in 80 women with Fitzpatrick skin types I-III and facial rosacea requiring prescription medication. After baseline measurements, subjects received six weeks of 0.75% metronidazole gel and were randomized to receive the nature-based regimen or control regimen, twice daily for four weeks.

“These data support the whole formula regimen of natural origin in the management of dermatologic conditions, such as rosacea, that require prescription medication” said Hemali Gunt, PhD, Head of Clinical and Scientific Affairs, at Burt’s Bees. “This work further affirms our innovations in whole formulas, designed to provide functional ingredients to restore and protect the skin, is ideal for patients who seek an alternative to conventional skin care products for the management of rosacea.”

Burt’s Bees will present three abstracts featuring trial data at the American Academy of Dermatology (AAD) Annual Meeting being held March 1-5, 2019, at the Walter E. Washington Convention Center in Washington, D.C.

Poster#10010: Adjunctive Use of Nature-Based Skin Care Products with Prescription Therapy According to Rosacea Severity. Hemali Gunt, PhD1, Zoe Diana Draelos, MD2, Stanley B. Levy, MD3
1Burt's Bees, Durham, NC; 2Dermatology Consulting Services, PLLC High Point, NC; 3Chapel Hill Dermatology, Chapel Hill, NC,

Poster #10183: Nature-Based Skin Care Products as an Adjunct Therapy Improve Epidermal Function in Moderate to Severe Rosacea Treated with Metronidazole. Hemali Gunt, PhD1, Zoe Diana Draelos, MD2, Stanley B. Levy, MD3. 1Burt's Bees, Durham, NC; 2Dermatology Consulting Services, PLLC High Point, NC; 3Chapel Hill Dermatology, Chapel Hill, NC

Poster #10186: Role of Nature-Based Skin Care Products as Adjunct Therapy in Subjects with Moderate to Severe Rosacea. Zoe Diana Draelos, MD1, Hemali Gunt, PhD2, Stanley B. Levy, MD3. 1Dermatology Consulting Services, PLLC High Point, NC; 2Burt's Bees, Durham, NC; 3Chapel Hill Dermatology, Chapel Hill, NC.

About the study | This study was single site, controlled, product-blinded and performed on 80 female subjects between 25-70 years of age possessing Fitzpatrick skin type’s I-III with facial rosacea requiring prescription medication. Subjects who met inclusion/exclusion criteria entered a 6-week open-label run in period in which they were treated with topical 0.75% metronidazole gel twice daily. No other topical or oral rosacea medications were allowed. Following baseline assessments of the investigator global rosacea assessment, investigator rated efficacy, evaporimetry for transepidermal water loss and corneometry for shin hydration; subjects were then randomized to receive 4 weeks of either the nature based sensitive skin regimen or the control regimen. The Burt’s Bees Skin Care Regimen included Burt’s Bees Sensitive Facial Cleanser (used twice daily), Burt’s Bees Sensitive Daily Moisturizing Cream (applied in the morning) and Burt’s Bees Sensitive Night Cream (used in the evening). The Control Skin Care Regimen included Cetaphil Gentle Skin Cleanser (used twice daily) and Cetaphil Moisturizing Lotion (used twice daily). Evaluations repeated at 2 and 4 weeks. Read the full-text citation: Draelos, ZD, Gunt, H, and Levy, SB. Natural skin care products as adjunctive to prescription therapy in moderate to severe rosacea. J Drugs Dermatol. 2019; 18(2):141-146. : LINK

About Burt’s Bees | Burt's Bees® has been offering distinctive earth-friendly, natural health and beauty care products for over 30 years. From a beekeeper's backyard in Maine to the leading edge of natural, Burt's Bees knows natural solutions for beauty from the inside out and operates with The Greater Good™ top of mind. Formulated without parabens, phthalates, petrolatum or SLS. No animal testing. To find out more, visit www.burtsbees.com. NYSE: CLX CLX-B.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190213005152/en/

MULTIMEDIA AVAILABLE:https://www.businesswire.com/news/home/20190213005152/en/